6 completed. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 1 | Completed 1 |
Follow Castration Levels of Testosterone: new trials by email Literature Review of Castration Levels of Testosterone trials Research Report on Castration Levels of Testosterone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer Apalutamide, Stereotactic Body Radiation Therapy - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | University of California, San Francisco | 26 | 2019-12-17 | 2026-01-21 |
| Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 15 | 2018-06-07 | 2023-05-03 |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer ESK981 - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 13 | 2018-03-08 | 2023-07-14 |
| Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway Carboplatin, Docetaxel, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | University of Washington | 14 | 2016-01-26 | 2022-11-17 |
| CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 54 | 2013-09-10 | 2019-07-09 |
| Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 170 | 2012-07-11 | 2021-07-30 |
Prostatic Neoplasms (4) · Lymphadenopathy (1)
Genital Diseases (4) · Genital Diseases, Male (4) · Genital Neoplasms, Male (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Prostatic Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Hemic and Lymphatic Diseases (1) · Lymphatic Diseases (1)
Carboplatin (2) · Docetaxel (1) · Radiosurgery (1) · XRP6258 (1) · apalutamide (1) · cabazitaxel (1) · pembrolizumab (1)
Barbara Ann Karmanos Cancer Institute (2) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · University of California, San Francisco (1) · University of Washington (1)
United States (6)
Abhinav Deol, M.D. (1) · Elisabeth I. Heath (1) · Heather H. Cheng (1) · Lawrence Fong (1) · Martin A. Cheever (1) · Paul Corn (1) · Rahul Aggarwal, MD (1)
PMID 31515154, PMID 37981040, PMID 39227508
P30CA015704 (2), P30CA022453 (2), P50CA097186 (2), P30CA016672 (1), U01CA154967 (1)